Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARGON-2
2019-003876-38Phase 2Terminated
- Sponsor
- Enanta Pharmaceuticals
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD) comparing EDP-305 with Placebo (2 arms). Started Feb 2020; status: terminated.
02
Drugs
EDP-305
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2019-003876-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003876-38.